Pine C. Michael's most recent trade in EyePoint Pharmaceuticals Inc was a trade of 42,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 5, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| EyePoint Pharmaceuticals Inc | Pine C. Michael | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | C. Michael Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Pine C. Michael | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | C. Michael Pine | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 19,628 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Pine C. Michael | Chief Corp Dev.&Strat. Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 5,966 | 13,662 (0%) | 0% | 20.4 | 121,706 | Common Stock |
| EyePoint Pharmaceuticals Inc | Pine Michael C. | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2023 | 45,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | C. Pine Michael | Chief Corp Dev.&Strat. Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.62 per share. | 04 Dec 2023 | 45,000 | 50,343 (0%) | 0% | 12.6 | 567,900 | Common Stock |
| EyePoint Pharmaceuticals Inc | Michael C. Pine | Chief Corp Dev.&Strat. Officer | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 04 Dec 2023 | 45,000 | 5,343 (0%) | 0% | 22 | 990,000 | Common Stock |
| EyePoint Pharmaceuticals Inc | C. Michael Pine | Chief Corp Dev.&Strat. Officer | Sale of securities on an exchange or to another person at price $ 20.79 per share. | 04 Dec 2023 | 1,000 | 4,343 (0%) | 0% | 20.8 | 20,790 | Common Stock |
| EyePoint Pharmaceuticals Inc | Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 45,855 | 45,855 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 91,655 | 91,655 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Michael C. Pine | Chief Corp Dev.&Strat. Officer | Purchase of securities on an exchange or from another person at price $ 12.21 per share. | 14 Mar 2022 | 1,000 | 1,000 (0%) | 0% | 12.2 | 12,210 | Common Stock |
| EyePoint Pharmaceuticals Inc | Michael C. Pine | Chief Corp Dev.&Strat. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) |